Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LENZ TherapeuticsLENZ +0.19%12 EV-to-EBITDA is 0.76 as of Aug. 11, 2026. GuruFocus rates LENZ with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 402 Biotechnology companies, LENZ Therapeutics ranks better than 81.84% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, LENZ Therapeutics's enterprise value is $-89.65 Mil.
LENZ Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-117.98 Mil. Therefore, LENZ Therapeutics's EV-to-EBITDA for today is 0.76.
The historical rank and industry rank for LENZ Therapeutics's EV-to-EBITDA or its related term are showing as below:
LENZ'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.58 Med: -2.21 Max: 0.81
Current: 0.76
During the past 5 years, the highest EV-to-EBITDA of LENZ Therapeutics was 0.81. The lowest was -17.58. And the median was -2.21.
LENZ's EV-to-EBITDA is ranked better than 81.84% of 402
companies
in the Biotechnology industry
Industry Median: 13.3
vs LENZ: 0.76
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
LENZ Therapeutics's PE Ratio (TTM) for today is calculated as:
LENZ Therapeutics's share price for today is $5.36.
LENZ Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.600.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for LENZ Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, LENZ Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LENZ Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LENZ Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where LENZ Therapeutics's EV-to-EBITDA falls into.
LENZ Therapeutics's current Enterprise Value is $-89.65 Mil.
LENZ Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-117.98 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LENZ Therapeutics (LENZ) has a EV-to-EBITDA of 0.76 as of Aug. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on LENZ Therapeutics. According to the industry distribution chart, LENZ Therapeutics ranks #73 out of 402 companies in the Biotechnology industry, placing it in the top 18.2%.
Is LENZ Therapeutics' EV-to-EBITDA too high?
LENZ Therapeutics' current EV-to-EBITDA is 0.76. The Biotechnology industry median EV-to-EBITDA is 13.30. LENZ Therapeutics' value of 0.76 is 94.3% below this industry median. Based on the distribution chart, LENZ Therapeutics ranks #73 out of 402 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, LENZ Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LENZ Therapeutics' EV-to-EBITDA compare to NGEN and ARMP?
According to the Biotechnology industry distribution chart, LENZ Therapeutics ranks #73 out of 402 companies for EV-to-EBITDA. This places LENZ Therapeutics in the top 18% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.30. LENZ Therapeutics' value of 0.76 is 94.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.30, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LENZ Therapeutics's current EV-to-EBITDA of 0.76 is 94.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on LENZ Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 13.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LENZ Therapeutics's current EV-to-EBITDA is 0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LENZ Therapeutics stock overvalued right now?
LENZ Therapeutics (LENZ) has a current EV-to-EBITDA of 0.76. The current EV-to-EBITDA is 0.76 and 94.3% below the Biotechnology industry median of 13.30. LENZ Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For LENZ Therapeutics (LENZ), the current EV-to-EBITDA is 0.76 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
12GF Score
Get the complete analysis for LENZ
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LENZ has been successfully added to your 
